05Y Stock Overview
A clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Vivoryon Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.10 |
| 52 Week High | €9.81 |
| 52 Week Low | €0.40 |
| Beta | 1.99 |
| 11 Month Change | -11.95% |
| 3 Month Change | -8.89% |
| 1 Year Change | -73.78% |
| 33 Year Change | -88.61% |
| 5 Year Change | -60.00% |
| Change since IPO | -91.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 05Y | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.5% | -0.02% | -1.5% |
| 1Y | -73.8% | -17.7% | 7.9% |
Return vs Industry: 05Y underperformed the German Biotechs industry which returned -17.7% over the past year.
Return vs Market: 05Y underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 05Y volatility | |
|---|---|
| 05Y Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 05Y's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 05Y's weekly volatility has decreased from 30% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 15 | Frank Weber | www.vivoryon.com |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease.
Vivoryon Therapeutics N.V. Fundamentals Summary
| 05Y fundamental statistics | |
|---|---|
| Market cap | €54.35m |
| Earnings (TTM) | -€31.18m |
| Revenue (TTM) | n/a |
-15.0x
P/S Ratio-1.7x
P/E RatioIs 05Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 05Y income statement (TTM) | |
|---|---|
| Revenue | -€3.62m |
| Cost of Revenue | -€525.00k |
| Gross Profit | -€3.09m |
| Other Expenses | €28.09m |
| Earnings | -€31.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 85.50% |
| Net Profit Margin | 861.46% |
| Debt/Equity Ratio | 0% |
How did 05Y perform over the long term?
See historical performance and comparison